JENA, Germany, May 12 /CNW/ - Occlutech, the leading European developer
of septum occluders, today announced that it has obtained CE mark approval for
its new generation ASD and PFO occluders, the Figulla Flex.
The Figulla Flex ASD and PFO occluders encompass a new innovative
delivery system, making the use of a threaded hub unnecessary. The
implantation of the occluder is facilitated by the ability of the delivery
system to allow a 45 degree angle before release.
The Occlutech Figulla Flex will be exhibited and demonstrated at the PCR
vascular intervention meeting in Barcelona from May 19th to May 22nd.
Occlusion devices are used to treat structural heart disease, including
structural heart defects and abnormalities such as Atrial Septal Defects,
(ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's
two atria, present in up to 25% of the population), in minimally invasive,
non-surgical procedures. The market for PFO occluders is expected to expand
significantly as the link between PFO and stroke, that is the third most
common cause of death, as well as severe migraine becomes increasingly well
For further information:
For further information: Tor Peters, firstname.lastname@example.org, Tel:
+49-3641-67-51-29; Katrin Biedermann, email@example.com, Tel.: